Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALLO
Strong SellSinkerAllogene Therapeutics, Inc. · Healthcare · United States · $698M · Avg Vol: $9M/d
COMPANY DESCRIPTION
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic (off-the-shelf) CAR T cell therapies for cancer, aiming to provide a more scalable and accessible treatment option than autologous therapies. The company is a key innovator in the cellular immunotherapy space, leveraging its proprietary platform to advance multiple candidates for various hematologic malignancies and solid tumors, positioning itself to address a significant unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0.2M | 95.0K | 22.0K | 0 | -62.4% | — | 3.4M | 12.1M | 719.0% |
| EPS | -1.89 | -0.97 | -1.02 | -1.32 | -0.87 | — | -0.66 | -0.59 | -0.65 | — |
| Shares | — | 345.2M | 345.2M | 212.2M | 229.4M | -33.5% | — | — | — | — |
| Debt | — | 101.1M | 95.1M | 90.8M | 83.3M | -6.3% | 79.0M | — | — | — |
| Equity | — | 666.9M | 512.2M | 422.2M | 292.5M | -24.0% | — | — | — | — |
| Op CF | — | -220.5M | -237.7M | -200.3M | -149.2M | — | -102.2M | — | — | — |
| Inv CF | — | 106.2M | 163.3M | 75.7M | 95.6M | — | — | — | — | — |
| Fin CF | — | 3.0M | 95.7M | 116.7M | 30.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALLO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc.(you) | $698M | 11 | Strong Sell |
| CTMX | CytomX Therapeutics, Inc. | $699M | 11 | Strong Sell |
| RGNX | REGENXBIO Inc. | $638M | 9 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $701M | 7 | Strong Sell |
| PHAT | Phathom Pharmaceuticals, Inc. | $743M | 14 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $595M | 9 | Strong Sell |
| 950260.KQ | Ingenia Therapeutics Inc. | $649M | 7 | Strong Sell |
| STTK | Shattuck Labs, Inc. | $707M | 16 | Strong Sell |
| CABA | Cabaletta Bio, Inc. | $529M | 10 | Strong Sell |
| BLSM | BlossomHill Therapeutics, Inc. | $569M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%